EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients

作者： Helen N. Honma , Maurício W. Perroud , Maurício S. T. Leme , Aristóteles S. Barbeiro , Bruna A. Saad

关键词:

摘要: The aim of the study was to analyze frequency epidermal growth factor receptor (EGFR) mutations in Brazilian non-small cell lung cancer patients and correlate these with response benefit platinum-based chemotherapy (NSCLC). Our cohort consisted prospective NSCLCs who received (platinum derivates plus paclitaxel) at [UNICAMP], Brazil. EGFR exons 18–21 were analyzed tumor-derived DNA. Fifty included (25 adenocarcinoma). identified 6/50 (12 %) 6/25 (24 adenocarcinomas; representing a mostly self-reported White (82.0 southeastern population NSCLCs. Patients harboring exon 19 deletions or 21 L858R mutation found have higher chance platinum-paclitaxel (OR 9.67 [95 % CI 1.03–90.41], p = 0.047). We report activating typical NSCLC, which are similar that other countries Western European ethnicity. seem be predictive platinum-paclitaxel, additional studies needed confirm refute this relationship.

elsevierpure.com 本地加速

utsystem.edu 本地加速

springer.com LINK 下载加速

sci-hub.se PDF 下载加速

参考文章(25)

Sabine Danzinger, Martin Filipits, None, Biomarker – der Weg zur individualisierten Chemotherapie beim nicht-kleinzelligen Bronchialkarzinom Wiener Medizinische Wochenschrift. ,vol. 157, pp. 554- 561 ,(2007) , 10.1007/S10354-007-0483-X

Ilma Aparecida Paschoal, Lair Zambon, Carcinoma bronquico : analise de uma serie de casos atendidos no ambulatorio de oncopneumologia das disciplinas de pneumologia e cirurgia toraxica da Faculdade de Ciencias Medicas da Unicamp Biblioteca Digital da Unicamp. ,(1994)

Bruce E. Johnson, Pasi A. Jänne, Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer Cancer Research. ,vol. 65, pp. 7525- 7529 ,(2005) , 10.1158/0008-5472.CAN-05-1257

William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073

Frances A Shepherd, Rafael Rosell, Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 2, ,(2007) , 10.1097/01.JTO.0000269737.05962.A0

Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954

Chia-Chi Lin, Hsin-Hsin Hsu, Chia-Tung Sun, Jin-Yuan Shih, Zhong-Zhe Lin, Chong-Jen Yu, George G. Chen, Michael Kuan Yew Hsin, Kwok Chi Lam, Linda Leung, Chih-Hsin Yang, Tony Mok, Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors Journal of Thoracic Oncology. ,vol. 5, pp. 1424- 1429 ,(2010) , 10.1097/JTO.0B013E3181E9DB73

Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri, Lung cancer: New biological insights and recent therapeutic advances. CA: A Cancer Journal for Clinicians. ,vol. 61, pp. 91- 112 ,(2011) , 10.3322/CAAC.20102

Antonella De Luca, Adele Carotenuto, Annamaria Rachiglio, Marianna Gallo, Monica R. Maiello, Donatella Aldinucci, Antonio Pinto, Nicola Normanno, The role of the EGFR signaling in tumor microenvironment Journal of Cellular Physiology. ,vol. 214, pp. 559- 567 ,(2008) , 10.1002/JCP.21260

10.

Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Moran, Amelia Insa, Filippo De Marinis, Romain Corre, Isabel Bover, Alfonso Illiano, Eric Dansin, Javier De Castro, Michele Milella, Noemi Reguart, Giuseppe Altavilla, Ulpiano Jimenez, Mariano Provencio, Miguel Angel Moreno, Josefa Terrasa, Jose Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Domine, Olivier Molinier, Julien Mazieres, Nathalie Baize, Rosario Garcia-Campelo, Gilles Robinet, Delvys Rodriguez-Abreu, Guillermo Lopez-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, Pierre Bombaron, Reyes Bernabe, Alessandra Bearz, Angel Artal, Enrico Cortesi, Christian Rolfo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Jose Luis Ramirez, Jose Javier Sanchez, Miguel Angel Molina, Miquel Taron, Luis Paz-Ares, None, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. ,vol. 13, pp. 239- 246 ,(2012) , 10.1016/S1470-2045(11)70393-X

EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients

来源期刊

我的账户

EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients

来源期刊

相似文章 4

EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)

Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis.

Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.

我的账户